<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p164" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_164{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_164{left:306px;bottom:30px;}
#t3_164{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_164{left:346px;bottom:30px;}
#t5_164{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_164{left:517px;bottom:30px;}
#t7_164{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_164{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_164{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_164{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_164{left:35px;bottom:777px;letter-spacing:0.01px;word-spacing:0.17px;}
#tc_164{left:35px;bottom:754px;letter-spacing:0.13px;word-spacing:0.06px;}
#td_164{left:35px;bottom:731px;letter-spacing:0.15px;word-spacing:-1.19px;}
#te_164{left:409px;bottom:738px;letter-spacing:-0.01px;}
#tf_164{left:431px;bottom:731px;letter-spacing:0.29px;word-spacing:-0.1px;}
#tg_164{left:35px;bottom:707px;letter-spacing:0.08px;word-spacing:0.1px;}
#th_164{left:35px;bottom:684px;letter-spacing:0.13px;word-spacing:-0.36px;}
#ti_164{left:35px;bottom:661px;letter-spacing:0.15px;word-spacing:0.03px;}
#tj_164{left:35px;bottom:638px;letter-spacing:0.19px;}
#tk_164{left:35px;bottom:614px;letter-spacing:0.17px;word-spacing:0.02px;}
#tl_164{left:385px;bottom:622px;letter-spacing:-0.01px;}
#tm_164{left:408px;bottom:614px;letter-spacing:0.19px;}
#tn_164{left:35px;bottom:591px;letter-spacing:0.17px;word-spacing:0.02px;}
#to_164{left:35px;bottom:568px;word-spacing:0.19px;}
#tp_164{left:35px;bottom:545px;letter-spacing:0.15px;word-spacing:0.04px;}
#tq_164{left:277px;bottom:545px;}
#tr_164{left:293px;bottom:545px;letter-spacing:0.07px;word-spacing:0.12px;}
#ts_164{left:35px;bottom:522px;letter-spacing:0.05px;word-spacing:-1.1px;}
#tt_164{left:35px;bottom:498px;letter-spacing:0.08px;word-spacing:0.11px;}
#tu_164{left:35px;bottom:475px;letter-spacing:0.21px;word-spacing:-0.03px;}
#tv_164{left:385px;bottom:483px;letter-spacing:-0.01px;}
#tw_164{left:35px;bottom:436px;letter-spacing:0.14px;word-spacing:-0.77px;}
#tx_164{left:35px;bottom:413px;letter-spacing:0.12px;word-spacing:0.06px;}
#ty_164{left:35px;bottom:390px;letter-spacing:0.15px;word-spacing:0.04px;}
#tz_164{left:35px;bottom:366px;letter-spacing:0.11px;word-spacing:-0.06px;}
#t10_164{left:35px;bottom:343px;letter-spacing:0.06px;word-spacing:0.12px;}
#t11_164{left:132px;bottom:351px;letter-spacing:-0.01px;}
#t12_164{left:155px;bottom:343px;letter-spacing:0.09px;word-spacing:0.09px;}
#t13_164{left:35px;bottom:320px;letter-spacing:0.09px;word-spacing:0.1px;}
#t14_164{left:483px;bottom:320px;}
#t15_164{left:499px;bottom:320px;letter-spacing:0.21px;word-spacing:-0.04px;}
#t16_164{left:35px;bottom:280px;letter-spacing:0.09px;word-spacing:0.1px;}
#t17_164{left:35px;bottom:256px;letter-spacing:0.11px;word-spacing:0.07px;}
#t18_164{left:35px;bottom:233px;letter-spacing:0.04px;word-spacing:0.14px;}
#t19_164{left:35px;bottom:210px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1a_164{left:35px;bottom:187px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1b_164{left:271px;bottom:194px;letter-spacing:0.1px;}
#t1c_164{left:317px;bottom:187px;letter-spacing:0.17px;word-spacing:0.01px;}
#t1d_164{left:35px;bottom:163px;letter-spacing:0.12px;word-spacing:-1.15px;}
#t1e_164{left:340px;bottom:171px;}
#t1f_164{left:350px;bottom:163px;letter-spacing:0.15px;word-spacing:0.03px;}
#t1g_164{left:35px;bottom:140px;letter-spacing:0.07px;word-spacing:-1.11px;}
#t1h_164{left:551px;bottom:148px;letter-spacing:-0.11px;}
#t1i_164{left:35px;bottom:101px;letter-spacing:0.08px;word-spacing:-0.03px;}
#t1j_164{left:35px;bottom:78px;letter-spacing:0.15px;word-spacing:-0.08px;}
#t1k_164{left:35px;bottom:55px;letter-spacing:0.18px;word-spacing:-0.2px;}
#t1l_164{left:618px;bottom:777px;letter-spacing:0.15px;word-spacing:0.03px;}
#t1m_164{left:618px;bottom:754px;letter-spacing:0.08px;word-spacing:-0.97px;}
#t1n_164{left:618px;bottom:731px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1o_164{left:618px;bottom:707px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1p_164{left:618px;bottom:684px;letter-spacing:0.17px;word-spacing:0.01px;}
#t1q_164{left:618px;bottom:661px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1r_164{left:618px;bottom:638px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1s_164{left:862px;bottom:638px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1t_164{left:618px;bottom:614px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1u_164{left:737px;bottom:622px;letter-spacing:0.08px;}
#t1v_164{left:826px;bottom:614px;letter-spacing:0.11px;word-spacing:0.07px;}
#t1w_164{left:618px;bottom:591px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1x_164{left:618px;bottom:568px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1y_164{left:1115px;bottom:576px;letter-spacing:0.1px;}
#t1z_164{left:618px;bottom:545px;letter-spacing:0.14px;word-spacing:0.05px;}
#t20_164{left:618px;bottom:522px;letter-spacing:0.12px;word-spacing:0.07px;}
#t21_164{left:618px;bottom:498px;letter-spacing:-0.05px;word-spacing:0.24px;}
#t22_164{left:618px;bottom:475px;letter-spacing:0.15px;word-spacing:0.03px;}
#t23_164{left:618px;bottom:452px;letter-spacing:0.13px;word-spacing:0.06px;}
#t24_164{left:917px;bottom:459px;letter-spacing:0.1px;}
#t25_164{left:618px;bottom:410px;letter-spacing:-0.21px;word-spacing:2.7px;}
#t26_164{left:618px;bottom:382px;letter-spacing:0.24px;}
#t27_164{left:618px;bottom:353px;letter-spacing:0.45px;}
#t28_164{left:654px;bottom:353px;letter-spacing:0.12px;word-spacing:0.06px;}
#t29_164{left:823px;bottom:353px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2a_164{left:618px;bottom:330px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2b_164{left:618px;bottom:306px;letter-spacing:0.11px;word-spacing:-0.13px;}
#t2c_164{left:618px;bottom:283px;letter-spacing:0.08px;word-spacing:0.1px;}
#t2d_164{left:618px;bottom:260px;letter-spacing:0.08px;word-spacing:-0.88px;}
#t2e_164{left:926px;bottom:268px;letter-spacing:0.1px;}
#t2f_164{left:972px;bottom:260px;letter-spacing:-0.01px;word-spacing:0.19px;}
#t2g_164{left:618px;bottom:237px;letter-spacing:0.12px;word-spacing:0.06px;}
#t2h_164{left:618px;bottom:214px;letter-spacing:0.06px;word-spacing:-0.93px;}
#t2i_164{left:618px;bottom:190px;letter-spacing:0.2px;word-spacing:-0.01px;}
#t2j_164{left:618px;bottom:150px;letter-spacing:0.1px;word-spacing:-0.94px;}
#t2k_164{left:618px;bottom:128px;letter-spacing:0.16px;word-spacing:0.03px;}
#t2l_164{left:618px;bottom:105px;letter-spacing:0.18px;}
#t2m_164{left:618px;bottom:82px;letter-spacing:0.08px;}
#t2n_164{left:654px;bottom:89px;letter-spacing:0.1px;}
#t2o_164{left:699px;bottom:82px;letter-spacing:0.05px;word-spacing:0.13px;}
#t2p_164{left:618px;bottom:58px;letter-spacing:0.09px;word-spacing:-1.14px;}
#t2q_164{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_164{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_164{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_164{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_164{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_164{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_164{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_164{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_164{font-size:20px;font-family:Arial-BoldMT_5te;color:#000;}
.s8_164{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts164" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg164Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg164" style="-webkit-user-select: none;"><object width="1210" height="935" data="164/164.svg" type="image/svg+xml" id="pdf164" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_164" class="t s0_164">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_164" class="t s1_164">© </span>
<span id="t3_164" class="t s0_164">(NCCN </span>
<span id="t4_164" class="t s1_164">© </span>
<span id="t5_164" class="t s0_164">), All rights reserved. NCCN Guidelines </span>
<span id="t6_164" class="t s1_164">® </span>
<span id="t7_164" class="t s0_164">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_164" class="t s2_164">NCCN Guidelines Version 4.2024 </span>
<span id="t9_164" class="t s2_164">Head and Neck Cancers </span>
<span id="ta_164" class="t s3_164">MS-23 </span>
<span id="tb_164" class="t s4_164">larynx preservation rate at 3 months in patients with locally advanced </span>
<span id="tc_164" class="t s4_164">larynx or hypopharynx cancers who received either cisplatin (95%) or </span>
<span id="td_164" class="t s4_164">cetuximab (93%) with RT following induction TPF. </span>
<span id="te_164" class="t s5_164">314 </span>
<span id="tf_164" class="t s4_164">Although surgery for </span>
<span id="tg_164" class="t s4_164">persistent disease was feasible only in patients who received cetuximab </span>
<span id="th_164" class="t s4_164">with RT following TPF, rate of treatment failure was lower in patients who </span>
<span id="ti_164" class="t s4_164">received cisplatin with RT. Long-term results of this trial showed no </span>
<span id="tj_164" class="t s4_164">significant differences between the study arms for 5-year OS, LRC, and </span>
<span id="tk_164" class="t s4_164">laryngo-esophageal dysfunction-free survival. </span>
<span id="tl_164" class="t s5_164">315 </span>
<span id="tm_164" class="t s4_164">There were also no </span>
<span id="tn_164" class="t s4_164">significant differences in toxicities, although late toxicities tended to be </span>
<span id="to_164" class="t s4_164">more common in the cetuximab arm, compared to the cisplatin arm </span>
<span id="tp_164" class="t s4_164">(96.1% vs. 86.2% respectively; </span><span id="tq_164" class="t s6_164">P </span><span id="tr_164" class="t s4_164">= .10). A randomized phase III </span>
<span id="ts_164" class="t s4_164">noninferiority trial showed no differences in PFS, overall response rates, or </span>
<span id="tt_164" class="t s4_164">adverse event rates between cisplatin and cetuximab, delivered </span>
<span id="tu_164" class="t s4_164">concurrently with RT following induction TPF. </span>
<span id="tv_164" class="t s5_164">316 </span>
<span id="tw_164" class="t s4_164">Results of the phase III GORTEC 2007-02 trial, in which 370 patients with </span>
<span id="tx_164" class="t s4_164">bulky nodal disease (N2b, N2c, or N3) were randomized to receive </span>
<span id="ty_164" class="t s4_164">carboplatin/5-FU with RT or TPF followed by cetuximab/RT, showed no </span>
<span id="tz_164" class="t s4_164">significant differences between the study arms for survival outcomes and </span>
<span id="t10_164" class="t s4_164">local control. </span>
<span id="t11_164" class="t s5_164">317 </span>
<span id="t12_164" class="t s4_164">There was a trend towards a lower rate of distant </span>
<span id="t13_164" class="t s4_164">metastases in the TPF arm (HR, 0.54; 95% CI, 0.30–0.99; </span><span id="t14_164" class="t s6_164">P </span><span id="t15_164" class="t s4_164">= .05). </span>
<span id="t16_164" class="t s4_164">The panel recommends cetuximab administered concurrent with RT </span>
<span id="t17_164" class="t s4_164">following induction chemotherapy may also be used, but only in select </span>
<span id="t18_164" class="t s4_164">circumstances such as in patients who are cisplatin-ineligible. Weekly </span>
<span id="t19_164" class="t s4_164">cisplatin with RT following induction chemotherapy is a category 2B </span>
<span id="t1a_164" class="t s4_164">option, based on extrapolation. </span>
<span id="t1b_164" class="t s5_164">306,314 </span>
<span id="t1c_164" class="t s4_164">However, because of toxicity </span>
<span id="t1d_164" class="t s4_164">concerns, high-dose cisplatin (100 mg/m </span>
<span id="t1e_164" class="t s5_164">2 </span>
<span id="t1f_164" class="t s4_164">every 21 days × 3 doses) is not </span>
<span id="t1g_164" class="t s4_164">recommended with RT after induction cisplatin-based chemotherapy. </span>
<span id="t1h_164" class="t s5_164">305,314 </span>
<span id="t1i_164" class="t s4_164">The data summarized in this section highlights overarching concerns that </span>
<span id="t1j_164" class="t s4_164">any efficacy gains of an induction chemotherapy followed by RT strategy </span>
<span id="t1k_164" class="t s4_164">may be offset by the poorer patient adherence with the RT-based part of </span>
<span id="t1l_164" class="t s4_164">treatment and the alternative option of shorter duration, better-tolerated, </span>
<span id="t1m_164" class="t s4_164">and effective concurrent systemic therapy/RT regimens. Because of these </span>
<span id="t1n_164" class="t s4_164">uncertainties, enrollment of patients in appropriate clinical trials of </span>
<span id="t1o_164" class="t s4_164">induction chemotherapy is encouraged. Outside of a clinical trial, </span>
<span id="t1p_164" class="t s4_164">concurrent systemic therapy/RT—with high-dose cisplatin preferred—is </span>
<span id="t1q_164" class="t s4_164">considered the gold standard by many NCCN Panel Members (see </span>
<span id="t1r_164" class="t s6_164">Principles of Systemic Therapy </span><span id="t1s_164" class="t s4_164">in the NCCN Guidelines for Head and </span>
<span id="t1t_164" class="t s4_164">Neck Cancers). </span>
<span id="t1u_164" class="t s5_164">134-137,264,318 </span>
<span id="t1v_164" class="t s4_164">When induction chemotherapy is used, data </span>
<span id="t1w_164" class="t s4_164">show that the addition of a taxane to cisplatin/5-FU (of which TPF is the </span>
<span id="t1x_164" class="t s4_164">most extensively studied) is more efficacious than cisplatin/5-FU. </span>
<span id="t1y_164" class="t s5_164">304,313 </span>
<span id="t1z_164" class="t s4_164">Therefore, when used as induction chemotherapy for SCCHN, docetaxel </span>
<span id="t20_164" class="t s4_164">with cisplatin/5-FU is a category 1 preferred recommendation. </span>
<span id="t21_164" class="t s4_164">Paclitaxel/cisplatin/5-FU and carboplatin/paclitaxel/cetuximab are also </span>
<span id="t22_164" class="t s4_164">options for induction chemotherapy, though the latter is a category 2B </span>
<span id="t23_164" class="t s4_164">option based on less panel consensus. </span>
<span id="t24_164" class="t s5_164">299,319 </span>
<span id="t25_164" class="t s7_164">Principles of Supportive Care </span>
<span id="t26_164" class="t s3_164">Nutrition </span>
<span id="t27_164" class="t s4_164">The </span><span id="t28_164" class="t s6_164">Principles of Nutrition </span><span id="t29_164" class="t s4_164">section in the NCCN Guidelines for Head and </span>
<span id="t2a_164" class="t s4_164">Neck Cancers outlines nutritional management and supportive care for </span>
<span id="t2b_164" class="t s4_164">patients with H&amp;N cancers who are prone to weight loss, which can often </span>
<span id="t2c_164" class="t s4_164">be severe, as a result of treatment-related toxicity, disease, and health </span>
<span id="t2d_164" class="t s4_164">behaviors such as poor nutritional habits. </span>
<span id="t2e_164" class="t s5_164">320,321 </span>
<span id="t2f_164" class="t s4_164">Patients with H&amp;N cancers </span>
<span id="t2g_164" class="t s4_164">are also at risk for dehydration. The multidisciplinary expertise of a </span>
<span id="t2h_164" class="t s4_164">registered dietitian and a speech-language/swallowing therapist should be </span>
<span id="t2i_164" class="t s4_164">utilized throughout the continuum of care. </span>
<span id="t2j_164" class="t s4_164">Patients who have had significant weight loss (5% body weight loss over 1 </span>
<span id="t2k_164" class="t s4_164">month, or 10% body weight loss over 6 months) need nutritional </span>
<span id="t2l_164" class="t s4_164">evaluation and close monitoring of their weight to prevent further weight </span>
<span id="t2m_164" class="t s4_164">loss. </span>
<span id="t2n_164" class="t s5_164">322,323 </span>
<span id="t2o_164" class="t s4_164">In addition, all patients should receive nutritional evaluation </span>
<span id="t2p_164" class="t s4_164">before and after treatment to assess the need for interventions (eg, enteral </span>
<span id="t2q_164" class="t s8_164">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
